CGON icon

CG Oncology

26.72 USD
-0.39
1.44%
At close Jul 11, 4:00 PM EDT
After hours
26.72
+0.00
0.00%
1 day
-1.44%
5 days
2.45%
1 month
2.06%
3 months
38.59%
6 months
-6.83%
Year to date
-7.77%
1 year
-22.46%
5 years
-28.11%
10 years
-28.11%
 

About: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Employees: 113

0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

79% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 34

34% more call options, than puts

Call options by funds: $1.15M | Put options by funds: $859K

13% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 24

4.46% more ownership

Funds ownership: 88.38% [Q4 2024] → 92.84% (+4.46%) [Q1 2025]

1% more funds holding

Funds holding: 140 [Q4 2024] → 142 (+2) [Q1 2025]

8% less capital invested

Capital invested by funds: $1.9B [Q4 2024] → $1.74B (-$160M) [Q1 2025]

17% less funds holding in top 10

Funds holding in top 10: 12 [Q4 2024] → 10 (-2) [Q1 2025]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$23
14%
downside
Avg. target
$56
111%
upside
High target
$75
181%
upside

6 analyst ratings

positive
83%
neutral
17%
negative
0%
Morgan Stanley
Jeffrey Hung
110%upside
$56
Overweight
Maintained
17 Jun 2025
JP Morgan
Brian Cheng
53%upside
$41
Overweight
Initiated
2 May 2025
RBC Capital
Gregory Renza
154%upside
$68
Outperform
Maintained
29 Apr 2025
Cantor Fitzgerald
Josh Schimmer
181%upside
$75
Overweight
Reiterated
28 Apr 2025
HC Wainwright & Co.
Andres Maldonado
181%upside
$75
Buy
Reiterated
28 Apr 2025

Financial journalist opinion

Positive
Seeking Alpha
2 weeks ago
CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)
CG Oncology, Inc.'s cretostimogene shows strong efficacy and safety in late-stage bladder cancer trials, with promising complete response rates and durable activity. The company boasts a robust cash position, providing a multi-year runway and reducing near-term dilution risk as it approaches potential commercialization. Key risk remains the lack of randomized data for FDA approval, but I view the likelihood of approval as high given the compelling clinical results.
CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)
Neutral
GlobeNewsWire
1 month ago
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, June 10, 2025, at 11:20 am ET.
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Positive
Zacks Investment Research
1 month ago
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
Negative
Zacks Investment Research
1 month ago
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.36 per share a year ago.
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal in Cohort P with 90.5% high-grade recurrence free survival at 3 and 9 months by K-M -- New enrollment completion date for Phase 3 PIVOT-006 in intermediate-risk non-muscle invasive bladder cancer (NMIBC) expected in the second half of 2025 -- Initiated CORE-008 Cohort CX evaluating the combination of cretostimogene and gemcitabine in patients with high-risk (HR) BCG-exposed NMIBC - IRVINE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the first quarter ended March 31, 2025, and provided business updates.
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
Negative
Zacks Investment Research
2 months ago
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
CG Oncology, Inc. (CGON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Positive
Zacks Investment Research
2 months ago
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?
CG Oncology, Inc. (CGON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?
Positive
Benzinga
2 months ago
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why
75.5% complete response rate reported in BOND-003 Cohort C study for high-risk NMIBC patients unresponsive to BCG.
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why
Positive
Investors Business Daily
2 months ago
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug
Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer treatment.
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug
Neutral
GlobeNewsWire
2 months ago
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at AUA
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
Charts implemented using Lightweight Charts™